Back to Resources
Market Highlights
- During the first three quarters of 2025, companies in the European IgAN market focused on education and regulatory updates. All pieces were digital and targeted healthcare professionals.
- Filspari received standard EU approval and NICE draft guidance, supported by phase III PROTECT data, and emphasized its status as the only approved non-immunosuppressive DEARA for IgAN in Europe. CSL also highlighted its commitment to the rare disease community.
- Kinpeygo’s 2024 full EU approval with an expanded patient population was discussed, and the brand was positioned as the first and only approved disease-modifying treatment for IgAN in Europe.
Questions about this SnapShot or other markets?
U.S. MARKETS
Christine Alongi
alongi@dtwresearch.com
GLOBAL MARKETS
Robin Cefalo
cefalo@dtwresearch.com
SOCIAL MEDIA MARKETS
Andrew Carney
carney@dtwresearch.com